According to UnivDatos, the rising life sciences R&D investment, expansion of functional genomics research, growing focus on precision and rare disease therapeutics, increasing demand for cost-effective target validation in drug discovery, strengthening academic–industry collaborations, advancements in RNA delivery and stability technologies, and improving biomedical research infrastructure drive the Southeast Asia RNAi Technology market. As per the “Southeast Asia RNAi Technology Market” report, the market was valued at ~USD 80.20 million in 2024, growing at a CAGR of about 16.25% during the forecast period from 2025 to 2033 to reach USD million by 2033.

RNA interference technology (RNAi) has become a key facilitator of gene functional studies and therapeutic-focused studies in Southeast Asia. The region is also experiencing a steady increase in the adoption of RNAi, with the increasing life sciences R&D spending and the growing genomics architecture. RNAi is being incorporated into research and discovery processes in academic institutions, biotechnology companies, and pharmaceutical companies. This has led to the market developing into a strategically based segment of the larger biotech world in Southeast Asia.

Market Structure and Competitive Environment

The Southeast Asia RNAi Technology market is moderately consolidated, with multinational life sciences companies alongside regional manufacturers and suppliers. International companies offer standard, high-quality RNAi products and proven technology, whereas domestic companies generate value through local production, a speedy delivery cycle, and application tailoring. This mix leads to an ecosystem that is competitive and collaborative, where each company is not priced out but rather differentiated by the breadth of its products, technical support, and its ability to meet local research requirements.

On December 2, 2025, Thermo Fisher Scientific Inc., the world leader in serving science, announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and expanding its existing Bioprocess Design Centers in Incheon, Korea, and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency, and sustainability in biomanufacturing.

In Singapore, the country’s expanded facility provides access to bench-to-pilot scale bioprocessing, expert-led training, and deep collaborations with Thermo Fisher’s technical teams to scale early-stage processes, supporting flexible and sustainable biomanufacturing.

Role of RNAi in Research and Drug Discovery

RNAi technologies, especially siRNA-based technologies, are penetrating into functional genomics, as well as early-phase drug discovery processes in Southeast Asia. Pharmaceutical and biotechnology corporations use RNAi to enhance rapid target validation, minimize risks in the development stage, and enhance the efficiency in the pipeline. Meanwhile, there is an increase in RNAi application at academic and translational research institutes in the study of gene functions and in disease modeling. This mixed commercial and non-commercial demand by end-users enhances the stability of the market and provides the technology providers with recurrent revenues.

For example, on April 23, 2025, GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore's premier biotech incubator, announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector. Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/southeast-asia-rnai-technology-market?popup=report-enquiry

Regional Hubs Driving Adoption

Singapore is leading Southeast Asian RNAi technology because of its established biomedical ecosystem, strong IP protection, and a government that is proactive and supportive of advanced therapeutics. The availability of global life science companies, RNA and genomics research institutes, and translational medicine programs enhances the adoption of RNAi in discovery and early clinical stages. Time-to-market is also minimized by local supply of quality reagents, CDMO assistance, and talent. Moreover, Singapore is the key commercialization hub for RNAi technology in the region, serving as a regional headquarters and an innovative hub.

For example, on December 1, 2025, Precision Health Research, Singapore (PRECISE) announced a landmark partnership with companies Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk, under Phase II of Singapore’s National Precision Medicine (NPM) programme. This pioneering initiative marks Singapore as the first country in Asia to establish a pre-competitive collaboration with leading pharmaceutical companies, contributing to a vibrant precision health ecosystem and reaffirming Singapore as a leading hub for precision medicine innovation in Asia.

Vietnam is expected to grow at a significant CAGR during the forecast period (2025-2033). This is propelled by booming pharmaceutical production, increased investment in life sciences, and biotech policy reforms. The growing demand for RNAi tools in functional genomics and drug discovery is driven by increased collaboration among universities, hospitals, and private research institutions. The rise in international partnerships and technology transfer, and government incentives for high-tech and biopharma R&D, drives the growth of the Vietnam Market.

Strategic Alliances and Expansion Strategies

Strategic partnerships have characterized the Southeast Asia RNAi Technology market. The companies are also establishing partnerships with research institutes, contract research organizations, and local distributors to gain access to a broader market and an in-depth understanding of applications. There is also an increasing investment in regional production, technical training, and customer service stations. These plans enhance market penetration and establish long-term ties with end users, which is of extreme importance in research-based markets.

Trajectory Outlook for RNAi Innovation in Southeast Asia

The Southeast Asia RNAi Technology is at a stage of continuous growth, as substantiated by the expansion of genomics research, the intensification of local ecosystems, and the increase in the number of industry players. Also, the localization strategy, partnerships, and application-based innovation are competitive forces shaping the market, not by sheer scale. With the continued proliferation of its applications across research and commercial sectors, RNAi is emerging as a cornerstone of the region's life sciences value chain. In the future, strategic focus on regional priorities will play a key role in long-term market positioning.

Related Reports:-

MicroRNA (miRNAs) Market: Current Analysis and Forecast (2021-2027)

NGS Sample Preparation Market: Current Analysis and Forecast (2021-2027)

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/